TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20858746

Group type: EXPERIMENTAL
Intervention: Ethanol, n‐butanol, or n‐hexanol (3‐s pulses, 9 pulses total)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (3‐s pulses of clean air interspersed)
Number of subjects: 0
Study: 18245143

Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised exercise training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Weekly telephone support (control)
Number of subjects: 57
Study: 16015276

Group type: EXPERIMENTAL
Intervention: Vinegar (18 mmol acetic acid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vinegar (23 mmol acetic acid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vinegar (28 mmol acetic acid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low and intermediate levels of vinegar
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference meal (bread without vinegar)
Number of subjects: 12
Study: 12885487

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily
Number of subjects: 1756

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756
Study: 9890407

Group type: EXPERIMENTAL
Intervention: 0.5 mg nicorandil
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.2 mg nitroglycerin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Additional application of nicorandil after nitroglycerin
Number of subjects: 33
Study: 8526698

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (80 mmol/d)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 1804576

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d. perorally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6871129

Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 76
Study: 31721666

Group type: EXPERIMENTAL
Intervention: Sterile polyacrylate wound dressing with activated carbon cloth
Number of subjects: 248

Group type: COMPARATOR
Intervention: Hydrocellular foam dressing with silver
Number of subjects: 248
Study: 26894591

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (Group-2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (Group-4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg (Group-16)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sugammadex (all groups)
Number of subjects: 60
Study: 25946210

Group type: EXPERIMENTAL
Intervention: Superficial ablation (area A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Deep rejuvenation (area B)
Number of subjects: 25
Study: 23519233

Group type: COMPARATOR
Intervention: Resistance Training Athletes (RTA)
Number of subjects: 22
Study: 21745121

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 6689

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6689
Study: 19101420

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (phacoemulsification with intraocular lens implantation alone)
Number of subjects: 68
Study: 16441730

Group type: EXPERIMENTAL
Intervention: Dentifrice containing bioactive glass (NovaMin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo control dentifrice
Number of subjects: 100
Study: 15210260

Group type: EXPERIMENTAL
Intervention: Counseled group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 90
Study: 11083260

Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single DMARD therapy with or without prednisolone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs
Number of subjects: 195
Study: 9122365

Group type: EXPERIMENTAL
Intervention: 50 mg thiamine daily for 2 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8452112

Group type: EXPERIMENTAL
Intervention: Fast neutron radiation (mixed-beam treatment schedule)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional photon radiation
Number of subjects: 91
Study: 3780991

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 158

Group type: COMPARATOR
Intervention: Polypectomy or local excision
Number of subjects: 158
Study: 31873776

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Shaker exercises
Number of subjects: 50
Study: 30096702

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin (SP): S‐1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Capecitabine plus cisplatin (XP): capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w)
Number of subjects: 110
Study: 28946892

Group type: EXPERIMENTAL
Intervention: SuperPath approach
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional posterior approach
Number of subjects: 92
Study: 25730028

Group type: EXPERIMENTAL
Intervention: IMRT plus DC-CIK immunotherapy (study group, N = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: IMRT only (control group, N = 34)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IMRT plus DC-CIK immunotherapy (study group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: IMRT only (control group)
Number of subjects: 68
Study: 23452966

Group type: EXPERIMENTAL
Intervention: Extraction of the maxillary first premolars (group 1, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No extractions (group 2, n=25)
Number of subjects: 50
Study: 21594659

Group type: EXPERIMENTAL
Intervention: 150 µg clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18833168

Group type: EXPERIMENTAL
Intervention: Proflusak (fluoxetine)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 16497649

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cefuroxime-axetil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Unilateral AOM
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bilateral AOM
Number of subjects: 90
Study: 14959468

Group type: EXPERIMENTAL
Intervention: Nifedipin‐retard (40 mg/day, 20 mg twice a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipin‐retard (20 mg/day) in combination with metoprolol (100 mg/day, 50 mg twice a day)
Number of subjects: 20
Study: 15562712

Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study: 9876189

Group type: EXPERIMENTAL
Intervention: 0-6 month group
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0-12 month group
Number of subjects: 96
Study: 8025366

Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (2510 kJ/24 h) for 6 h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution (2510 kJ/24 h) for 6 h
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hypocaloric glucose
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (2510 kJ/24 h) for 6 h in healthy volunteers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution (2510 kJ/24 h) for 6 h in healthy volunteers
Number of subjects: 26
Study: 2605386

Group type: EXPERIMENTAL
Intervention: 0.8 mm vented mould
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 2 mm vented mould
Number of subjects: 106

Group type: COMPARATOR
Intervention: Unvented mould
Number of subjects: 106
Study: 31150574

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1052
Study: 28632545

Group type: EXPERIMENTAL
Intervention: CAMISS-TLIF
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open TLIF
Number of subjects: 61
Study: 25391616

Group type: EXPERIMENTAL
Intervention: Treatment-focused genetic testing (TFGT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-genetic health professionals' preference for information delivery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Barriers to implementation of TFGT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Future of TFGT in clinical care
Number of subjects: 36
Study: 24103725

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham acupressure wristbands
Number of subjects: 26
Study: 21362184

Group type: EXPERIMENTAL
Intervention: Trial participants (invited from population registers)
Number of subjects: 202638

Group type: COMPARATOR
Intervention: Invited population (not participating)
Number of subjects: 202638
Study: 19499960

Group type: COMPARATOR
Intervention: olmesartan/placebo
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 20 mg/5 mg
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 20 mg/10 mg
Number of subjects: 538
Study: 17898352

Group type: COMPARATOR
Intervention: Glycine
Number of subjects: 157

Group type: COMPARATOR
Intervention: D-cycloserine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 15485012

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 11535993

Group type: EXPERIMENTAL
Intervention: Lenograstim (250 microg/m(2))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Filgrastim (250 microg/m(2))
Number of subjects: 11
Study: 9506856

Group type: EXPERIMENTAL
Intervention: 25 microg T4 daily for two months (Group C)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 50 microg T4 daily for two months (Group D)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 25 microg T4 daily for two months (Group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 50 microg T4 daily for two months (Group B)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Thyroxine administration in group D (ThAab negative)
Number of subjects: 110
Study: 8090162

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 359

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 359
Study: 31968068

Group type: EXPERIMENTAL
Intervention: Digital CBT-I
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 208
Study: 29777975

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (BEV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 102
Study: 27469414

Group type: EXPERIMENTAL
Intervention: NeuroAiD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24895144

Group type: EXPERIMENTAL
Intervention: Fostamatinib (100 mg bid)
Number of subjects: 3
Study: 21562819

Group type: EXPERIMENTAL
Intervention: Leucine (250 mg/kg bm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 20617176

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 282

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Fungal infections (other than pneumocystis)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Baseline CD4+ T-cell counts
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: On-treatment CD4+ T-cell counts
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Baseline HIV RNA levels
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: On-treatment HIV RNA levels
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Corticosteroids during OI management
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Timing of ART
Number of subjects: 282
Study: 18479895

Group type: EXPERIMENTAL
Intervention: Indacaterol 400microg
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Indacaterol 200microg
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Indacaterol 50microg
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Indacaterol 100microg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Tiotropium 18microg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 15735210

Group type: EXPERIMENTAL
Intervention: Regular supervised physical exercise training
Number of subjects: 297

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 297
Study: 12540386

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (4 g/d, consisting of 45% eicosapentaenoic acid and 39% docosahexaenoic acid as ethyl esters)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (4 g/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (corn oil, 4 g/d)
Number of subjects: 24
Study: 11052029

Group type: EXPERIMENTAL
Intervention: Hydrocolloid barrier
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Nonhydrocolloid barrier
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (taped directly to skin)
Number of subjects: 148
Study: 8829930

Group type: EXPERIMENTAL
Intervention: EMLA 5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EMLA 5% plus glyceryl trinitrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study: 1856147

Group type: EXPERIMENTAL
Intervention: Amikacin given once daily (od)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amikacin given twice daily (bd)
Number of subjects: 0
Study: 6614032

Group type: EXPERIMENTAL
Intervention: intensive feedback
Number of subjects: 64

Group type: COMPARATOR
Intervention: videotape control
Number of subjects: 64

Group type: COMPARATOR
Intervention: questionnaire feedback
Number of subjects: 64

Group type: COMPARATOR
Intervention: questionnaire control
Number of subjects: 64
Study: 30339721

Group type: EXPERIMENTAL
Intervention: Baby Triple P
Number of subjects: 112

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups (Baby Triple P and Care as usual)
Number of subjects: 112
Study: 26341303

Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (TP)
Number of subjects: 10603
Study: 24481679

Group type: EXPERIMENTAL
Intervention: Doxorubicin (single-agent)
Number of subjects: 84
Study: 22718083

Group type: EXPERIMENTAL
Intervention: Fetal telecardiology service
Number of subjects: 67
Study: 20493663

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 56
Study: 18317369

Group type: COMPARATOR
Intervention: NF + CAFF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: WAT + CAFF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CES + CAFF
Number of subjects: 7

Group type: COMPARATOR
Intervention: NF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg.kg body weight)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 7
Study: 16043426

Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Internal standard: Oxybutynin
Number of subjects: 20
Study: 11788381

Group type: EXPERIMENTAL
Intervention: L-Carnitine L-tartrate (2 g L-carnitine/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10027480

Group type: EXPERIMENTAL
Intervention: diltiazem retard (D)
Number of subjects: 256

Group type: COMPARATOR
Intervention: atenolol (A)
Number of subjects: 256
Study: 8835550

Group type: EXPERIMENTAL
Intervention: Early treatment with auranofin within one year of diagnosis of RA.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Delayed treatment with slow acting antirheumatic drugs (SAARD) after 8 months compared to the early treatment group.
Number of subjects: 137
Study: 2144236

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 30
Study: 7280753

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) administered intramuscularly before repeat BTM and gamma camera studies
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline administered before gamma camera studies
Number of subjects: 21
Study: 31649396

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Huff's manoeuvre
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: FIC presence
Number of subjects: 336
Study: 29542208

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, left DLPFC, 20 sessions over 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study: 27643343

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) for 8 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Office Blood Pressure Management
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 180
Study: 25187749

Group type: EXPERIMENTAL
Intervention: Myringoplasty alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Myringoplasty with cortical mastoidectomy
Number of subjects: 40
Study: 21804414

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (NPWT) applied to closed surgical incisions (Group B)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard postoperative dressings (Group A)
Number of subjects: 249
Study: 19920818

Group type: EXPERIMENTAL
Intervention: Rituximab plus CVP (R-CVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVP alone
Number of subjects: 0
Study: 18616675

Group type: EXPERIMENTAL
Intervention: Calvados (13% ethanol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Shochu (13% ethanol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Red wine (13% ethanol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Beer (5% ethanol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ALDH2 homozygotes
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ALDH2 heterozygotes
Number of subjects: 19
Study: 16395995

Group type: EXPERIMENTAL
Intervention: StatXact software for exact tests incorporating new methods for non-inferiority and confidence intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Berger and Boos confidence interval method for testing equality of two proportions
Number of subjects: 0
Study: 14571615

Group type: EXPERIMENTAL
Intervention: Zhifeng Huatan Pingxiao recipe (ZHPR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study: 10918719

Group type: COMPARATOR
Intervention: Parasympathetic function assessment (E:I ratio)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Parasympathetic function assessment (Valsalva ratio)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Parasympathetic function assessment (30:15 ratio)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diastolic blood pressure response to head-up tilt
Number of subjects: 35

Group type: COMPARATOR
Intervention: Heart rate response to head-up tilt
Number of subjects: 35

Group type: COMPARATOR
Intervention: Anxiety score
Number of subjects: 35
Study: 8812822

Group type: EXPERIMENTAL
Intervention: Intervention (CATCH program)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6000
Study: 1550035

Group type: EXPERIMENTAL
Intervention: Mixed meals containing 0, 33, 67, 100, and 134 kJ/kg fat‐free mass (0, 8, 16, 24, and 32 kcal/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed meals
Number of subjects: 0
Study: 3699692

Group type: EXPERIMENTAL
Intervention: Hypohydration (total restriction of water intake)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Euhydration (water intake of 20 ml/kg body weight)
Number of subjects: 36
Study: 30832713

Group type: EXPERIMENTAL
Intervention: Jin's three-needle acupuncture (JTN) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic acupuncture group (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JTN treatment
Number of subjects: 0
Study: 30295539

Group type: EXPERIMENTAL
Intervention: Mobile-bearing rotating-platform (RP) TKA
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) TKA
Number of subjects: 167
Study: 26965764

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (700 IU daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 24787471

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extravirgin olive oil
Number of subjects: 6705

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 6705

Group type: COMPARATOR
Intervention: Low-fat diet (control group)
Number of subjects: 6705
Study: 21778259

Group type: EXPERIMENTAL
Intervention: Formoterol-budesonide combined treatment (18/640 μg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose budesonide treatment (1,600 μg daily)
Number of subjects: 40
Study: 19747781

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, cisplatin, and BCNU (HD-CPB)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Intermediate-dose CPB (ID-CPB)
Number of subjects: 785
Study: 17432389

Group type: EXPERIMENTAL
Intervention: Three-month nightly splinting of the FPL muscle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unsplinted hand (control)
Number of subjects: 20
Study: 15929518

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus octreotide (50 g/hr for 48 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 105
Study: 11889006

Group type: EXPERIMENTAL
Intervention: Smoking a single cigarette
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 20
Study: 10202728

Group type: EXPERIMENTAL
Intervention: Non-preserved carboxymethylcellulose-based (carmellose) artificial tears
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-preserved balanced salt solution
Number of subjects: 10